eGenesis, a Cambridge, Mass.-based biotechnology company utilizing gene editing technologies for the development of safe and effective human-compatible organs to address the global organ shortage, completed a $100m Series B financing.
The round was led by Fresenius Medical Care Ventures (FMCV), with participation from new investors Leaps by Bayer, and Wellington Partners and existing investors Arch Venture Partners, Biomatics Capital, Alta Partners, and Khosla Ventures. In connection with the financing, Al Wiegman, Head of Ventures at FMCV, as well as Jürgen Eckhardt and Dr. Lucio Iannone, Director of Venture Investments at Leaps by Bayer, will join the eGenesis Board of Directors.
The company intends to use the funds to accelerate its kidney xenotransplant program into the clinic, as well as support advancement of a range of other xenotransplant programs across islet cell, liver, heart, and lung.
Led by Paul Sekhri, president and CEO, eGenesis uses gene editing technology such as CRISPR to directly address the key virology and immunology hurdles that have impeded xenotransplantation to date. The company is advancing an initial product toward the clinic for kidney transplant, with the longer-term potential of addressing a broader organ recipient population and expanding the applicability of xenotransplantation into other areas such as cell therapy.